PMID- 36160021
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - Comparison of effectiveness and safety of camrelizumab between HBV-related and 
      non-B, non-C hepatocellular carcinoma: A retrospective study in China.
PG  - 1000448
LID - 10.3389/fgene.2022.1000448 [doi]
LID - 1000448
AB  - Purpose: This study aimed to compare the clinical outcomes of camrelizumab in 
      hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) patients and 
      non-HBV, non-HCV hepatocellular carcinoma (NBNC-HCC) patients in China. Materials 
      and methods: A total of 54 patients with hepatocellular carcinoma who received 
      camrelizumab were included in this retrospective study from January 2019 to 
      December 2021. The patients were assigned to the HBV-HCC group (n = 28) and the 
      NBNC-HCC group (n = 26). The primary endpoints were overall survival (OS) and 
      progression-free survival (PFS), and the secondary endpoints were the objective 
      response rate (ORR), disease control rate (DCR), and adverse events (AEs). 
      Multivariate analysis using Cox proportional hazard regression was used to 
      identify independent prognostic factors. A nomogram model was subsequently 
      established based on independent prognostic factors. Results: The mean duration 
      of follow-up was 12.7 +/- 3.6 months. The median OS was not determined. The median 
      PFS in the HBV-HCC group was significantly longer than that in the NBNC-HCC group 
      (9.2 vs. 6.7 months, p = 0.003). The ORR and DCR in the HBV-HCC group were 
      significantly higher than those in the NBNC-HCC group (ORR, 28.6% vs. 7.7%, p = 
      0.048; DCR, 71.4% vs. 42.3%, p = 0.031). No significant differences in the total 
      incidence of AEs were found between the HBV-HCC group and the NBNC-HCC group 
      (75.0% vs. 69.2%, p = 0.224). Multivariate regression analysis identified 
      etiology, AFP level, and vascular invasion as independent prognostic factors (all 
      p < 0.05). Conclusion: Our findings demonstrate that camrelizumab is more 
      effective in HBV-HCC patients than in NBNC-HCC patients, with manageable safety.
CI  - Copyright (c) 2022 Liu, Qin, Xu, Wu, Lu, Zhou, Yao, Liu, Shao and Han.
FAU - Liu, Haonan
AU  - Liu H
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Qin, Xiaobing
AU  - Qin X
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Xu, Zhiyuan
AU  - Xu Z
AD  - Department of Emergency, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Wu, Meng
AU  - Wu M
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Lu, Tong
AU  - Lu T
AD  - Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, China.
FAU - Zhou, Shuang
AU  - Zhou S
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Yao, Nan
AU  - Yao N
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Liu, Suya
AU  - Liu S
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Shao, Yong
AU  - Shao Y
AD  - Department of General Surgery, The Affiliated Hospital of Xuzhou Medical 
      University, Xuzhou, China.
FAU - Han, Zhengxiang
AU  - Han Z
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220909
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC9500546
OTO - NOTNLM
OT  - camrelizumab
OT  - effectiveness
OT  - hepatitis B virus
OT  - hepatocellular carcinoma
OT  - immunotherapy
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/27 06:00
MHDA- 2022/09/27 06:01
PMCR- 2022/09/09
CRDT- 2022/09/26 17:43
PHST- 2022/07/22 00:00 [received]
PHST- 2022/08/24 00:00 [accepted]
PHST- 2022/09/26 17:43 [entrez]
PHST- 2022/09/27 06:00 [pubmed]
PHST- 2022/09/27 06:01 [medline]
PHST- 2022/09/09 00:00 [pmc-release]
AID - 1000448 [pii]
AID - 10.3389/fgene.2022.1000448 [doi]
PST - epublish
SO  - Front Genet. 2022 Sep 9;13:1000448. doi: 10.3389/fgene.2022.1000448. eCollection 
      2022.